FindTrial
Sign In

NIZ985

DRUG3 trials

Sponsors

Novartis Pharma AG, Novartis Pharmaceuticals

Conditions

Different types of advanced cancerIn Escalation: All Patients With Solid Tumors and LymphomaIn Expansion: Melanoma, Non-small Cell Lung CancerMetastatic and Advanced Solid Tumors

Phase 1

A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers
TerminatedNCT02452268
Novartis PharmaceuticalsMetastatic and Advanced Solid Tumors
Start: 2017-05-08End: 2022-03-07Updated: 2023-03-03
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
TerminatedNCT04261439
Novartis PharmaceuticalsIn Escalation: All Patients With Solid Tumors and Lymphoma, In Expansion: Melanoma, Non-small Cell Lung Cancer
Start: 2020-02-27End: 2023-12-27Updated: 2025-05-06
An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments
Active, not recruitingCTIS2023-508841-42-00
Novartis Pharma AGDifferent types of advanced cancer
Start: 2019-10-30Target: 75Updated: 2025-10-28

Related Papers

First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors
Journal for ImmunoTherapy of Cancer2023-10-0122 citations
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors
Journal for ImmunoTherapy of Cancer2021-11-0143 citations
Researcher Redefines IL-15 & Presses It Into Action Against Cancer
Oncology Times2020-10-29
Abstract CT082: Phase (Ph) I/Ib study of NIZ985 with and without spartalizumab (PDR001) in patients (pts) with metastatic/unresectable solid tumors
Cancer Research2019-07-013 citations
Abstract CT082: Phase (Ph) I/Ib study of NIZ985 with and without spartalizumab (PDR001) in patients (pts) with metastatic/unresectable solid tumors
Clinical Trials2019-07-012 citations
Treatment with native heterodimeric IL-15 increases cytotoxic lymphocytes and reduces SHIV RNA in lymph nodes
PLoS Pathogens2018-02-2378 citations